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arotid Ultrasound,
oronary Calcium, and
yslipidemia Patterns in
he MESA (Multi-Ethnic Study
f Atherosclerosis) Cohort*
. B. John Mancini, MD,† Jiri Frohlich, MD‡
ancouver, British Columbia, Canada
n this issue of the Journal, Paramsothy et al. (1) relate
oronary artery calcium (CAC) scores and intima-media
hickness (IMT) measurements to patterns of dyslipidemia.
ecause much of current practice is dictated by such
atterns, the authors did not attempt to take into account
amily history, physical findings, apolipoproteins, and other
ests to determine specific diagnoses such as heterozygous
amilial hypercholesterolemia or familial combined hyper-
ipidemia. Instead, the paper used operational definitions
ased on the dominant lipid abnormality (in order of
everity: a combination of high triglycerides [TG] and high
ow-density lipoprotein cholesterol [LDL-C], isolated high
DL-C, increased TG with low high-density lipoprotein
holesterol [HDL-C], termed dyslipidemia of metabolic
yndrome, isolated hyper-TG, and isolated low HDL). The
ohort is both contemporary and large (n  4,792), has an
See page 1034
ptimal proportion of women (53%), and substantial ethnic
iversity. Confounding of lipid patterns and imaging mea-
urements as a result of variability in duration, intensity, or
ype of lipid therapy was avoided by excluding pre-treated
atients. Patients with diabetes mellitus were also excluded,
hereby avoiding confounding by type and/or duration of
iabetes and avoiding controversies about vascular effects of
ypoglycemic agents. Furthermore, the study provides an
pportunity to compare 2 distinctly different and topical
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Medicine, Cardiovascular Imaging Research Core
aboratory, Vancouver Hospital, Vancouver, British Columbia, Canada; and the
Department of Pathology, St. Paul’s Healthy Heart/Prevention Clinic, University ofa
ritish Columbia, Vancouver, British Columbia, Canada. The authors have reported
hat they have no relationships to disclose.maging methods for assessing vascular damage, namely,
AC scores and measures of IMT. Because the main goal
f the study was to determine the relationship of the
yslipidemic patterns per se and the imaging measurements
f vascular disease, the authors adjusted for multiple, im-
ortant confounders. Thus, analysis in this large and im-
ortant cohort is methodologically sound. The main result,
ased on either CAC or IMT, suggests that elevation of
DL-C is indeed the dominant determinant of vascular
amage and isolated hyper-TG is not.
The ARIC (Atherosclerosis Risk in Communities) study
howed that hyper-TG was, at least in women, a predictor
f heart disease (2). The NOMAS (Northern Manhattan
tudy), however, failed to associate hyper-TG with carotid
laque formation (3). In the current paper, the categoriza-
ion process for assigning patients to only 1 of the dyslipi-
emia patterns created a group of hyper-TG patients with
elatively high HDL of 54 mg/dl, which may have played a
ole in failing to show vascular damage. The dyslipidemia of
etabolic syndrome group represents the more commonly
een pattern of high TG and low HDL-C. The CAC
coring in this group showed an increased relative risk of
revalent CAC compared with normal subjects, whereas
MT was indistinguishable from normal. In the isolated low
DL group, however, CAC scores were not abnormal,
hereas the IMT of the common carotid was thicker when
ompared with that of normal subjects. The contribution of
he differential sensitivity of the 2 methods, which is
urrently unresolved, to these discrepant findings cannot be
roperly assessed because IMT was based on continuous
easurements whereas CAC analyses were dichotomous,
sing a single Agatston cut-off score (4,5). At most, the
aper suggests that vascular effects of either isolated low
DL-C or the dyslipidemia of metabolic syndrome are not
ajor.
Despite the cohort’s ethnic diversity and the large pro-
ortion of women, it is surprising that results failed to show
ny effect of these critical factors. The current analysis
uggests that vascular damage is more the result of the
onfounding effects of other risk factors and clinical features
han of biological differences in dyslipidemia-induced vas-
ulopathy in men versus women or in differing ethnic
roups. Even so, current guidelines mandate interpretation
f IMT measurements with respect to sex and encourage
onsideration of race/ethnicity (6). The MESA (Multi-
thnic Study of Atherosclerosis) program is expected to
elp us understand these effects more fully in future analy-
es (6).
The authors chose a limited number of dyslipidemic
atterns. Analyses of concomitant high LDL-C, low
DL-C and high-TG, or elevated non-HDL or elevated
atios (i.e., LDL-C/HDL-C, total cholesterol/HDL-C,
nd TG/HDL-C) might have been valuable (7,8). Addi-
ionally, a prior publication from the MESA cohort has
lready provided a more detailed analysis of the effects of
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September 21, 2010:1042–4 The MESA CohortDL on IMT measures of vascular damage with emphasis
n the mechanistic role of LDL-C particle subclasses and
ize (9). So the expectation that only simple lipid measure-
ents might clarify mechanistic linkage with vascular dam-
ge may have been overly optimistic.
The dyslipidemia of metabolic syndrome was not limited to
atients meeting the formal criteria for the syndrome (10).
lthough waist circumference, fasting glucose, blood pressure
nd blood pressure therapy were used to adjust results, they
ere not used to identify a subgroup truly meeting metabolic
yndrome criteria. Such an analysis would have been instructive
o evaluate whether the constellation of lipid and nonlipid
eatures have a synergistic, adverse impact on vascular disease
r merely an additive one (11).
Lipid guidelines are very heavily focused on treatment of
DL-C, and this analysis suggests that this remains appropri-
te (12). Framingham risk scoring, reflecting relatively short-
erm risk, is currently used to determine the need for and
ggressiveness of LDL-C lowering. Determination of appro-
riate therapy in patients with low or moderate risk is a
ommon problem for which imaging studies are often used to
elp formulate a treatment plan. The Framingham risk scores
n this cohort were generally low (average of 7.8% to 11.3% for
ramingham-National Cholesterol Education Program coro-
ary heart disease risk per 10 years for all groups). While the
alue of IMT and CAC scoring in refining risk remains
ontroversial (13), analysis of Framingham risk and imaging
ndings with respect to the dyslipidemic patterns would have
een useful. Indeed, prior work from this group and others has
ighlighted the importance of short-term versus long-term risk
n detection of vascular damage (14).
The JUPITER (Justification for the Use of Statins in
rimary Prevention: An Intervention Trial Evaluating Ro-
uvastatin) trial forces reevaluation of lipid-centric risk
tratification (15). While the current paper suggests that
igh-sensitivity C-reactive protein (hs-CRP) did not mod-
late the relationship between the dyslipidemic patterns and
he measures of vascular damage, no comparison was un-
ertaken between patients who would have been eligible for
he JUPITER trial and 2 important groups not represented
n the JUPITER study, namely, subjects with high LDL-C
nd low hs-CRP, and subjects with high LDL-C and high
s-CRP.
Carotid ultrasound for the purpose of risk stratification
nd for assessing drug intervention is handicapped by
iversity of methodologies (16,17). These methods range
rom those that make measurements of near and far walls in
he common, internal, and external carotids and the bulb to
hose that make measurements only in the far wall of the
ommon carotid; and diffuse IMT is not always distin-
uished from focal plaque (18–23). Thus, the term IMT
epresents imprecise jargon. Focal plaque formation, when
resent, is likely the most important vascular abnormality.
hen not present, only the measurement of diffuse IMT is
vailable to phenotype a given patient. Both measurements,
herefore, are important to record but may differ in theresence of diverse cardiovascular risk factors. Figure 1 of
aramsothy et al. (1) shows that the IMT of the common
nd internal carotid generally track each other. However,
he confidence intervals for measures of the common carotid
re consistently and markedly tighter than for the internal
arotid. This variance may be due either to greater mea-
urement difficulties or to greater heterogeneity of pheno-
ypic findings (i.e., presence or absence of focal plaques) in
hat bed. Thus, insights into the relationship of plaque
ormation versus diffuse IMT with respect to the dyslipide-
ic patterns would have been instructive.
In conclusion, the MESA study investigators provide
eassuring evidence that LDL-C is the dominant lipid
eterminant of vascular damage. This rich database will
rovide further insights into controversial issues of vascular
ealth pertaining, for example, to the interplay between
yslipidemia and factors such as sex, ethnicity, hs-CRP, and
etabolic syndrome.
eprint requests and correspondence: Dr. G. B. John Mancini,
ancouver Hospital Research Pavilion, Room 489, 828 West 10th
venue, Vancouver, British Columbia, V5Z 1L8, Canada. E-mail:
ancini@interchange.ubc.ca.
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